- About ASENT
- Members Only
|Training In Neurotherapeutics Discovery & Development|
Applications are now being accepted for the 2018 offering of Training in Neurotherapeutics Discovery and Development for Academic Scientists, which will be held Wednesday, March 7 to Saturday, March 10 at the Hilton Washington DC/Rockville Hotel & Executive Meeting Center, Rockville, Maryland. The deadline for receipt is November 15, 2017.
About This Training Program
We are happy to offer a 3½-day short course to introduce academic researchers to the principles of neurotherapeutic drug discovery and development.
The course covers the principles of drug discovery and development, including the identification of a lead compound and IND enabling studies. The course consider the discovery and development of small molecule therapies and also special considerations that apply to biological therapies, such as antibodies, antisense oligonucleotides, gene therapies and cell therapies. The course will also address the unique challenges inherent in developing treatments for nervous system disorders and will address the particular challenges that academic neuroscientists are likely to face in planning and conducting drug discovery research. Please note, however, that the course curriculum does not address clinical trials.
Participants who attend the short course program will have ongoing access to senior faculty who will assist the trainee to achieve success in their individual drug development projects.
Although we anticipate that most applicants will be advanced postdoctoral fellows or junior faculty members, any academic investigator who would benefit from the course is invited to apply. Basic researchers and clinician scientists are eligible. Mid-career and senior faculty who are interested in pursuing a new research direction of neurotherapeutics discovery and development are encouraged to apply. There is no tuition or registration fee and all travel expenses will be defrayed for successful applicants. The course will be offered annually.
We are excited to have the opportunity to offer this course, which we believe will help to advance the availability of new drugs for patients with neurological and psychiatric disorders. If your work would benefit from an understanding of how neurotherapeutic drugs are discovered, characterized and tested so that they can enter clinical trials, you are encouraged to apply.
Michael A. Rogawski, MD, PhD
Supported by National Institute of Neurological Disorders and Stroke Grants 1R25NS077582 and 1R25NS099170.